T1	Participants 66 131	HIV-infected adults with a toll-like receptor 9 agonist adjuvant:
T2	Participants 176 232	Persons infected with human immunodeficiency virus (HIV)
T3	Participants 494 514	HIV-infected adults.
T4	Participants 602 623	HIV-positive patients
T5	Participants 1197 1250	Ninety-seven participants were included in the study.
